BioCryst to Present at Upcoming Investor Conferences

February 21, 2024

RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the TD Cowen 44th Annual Health Care Conference in Boston on Wednesday, March 6, 2024, at 10:30 a.m. ET and the Barclays 26th Annual Global Healthcare Conference in Miami on Tuesday, March 12, 2024, at 7:30 a.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on LinkedIn.


John Bluth
+1 919 859 7910